Atte Junnila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Atte Junnila has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Anssi-Pekka Karttunen
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
5 shared publications Leena Peltonen
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki, Finland
5 shared publications- Tapani Viitala
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
4 shared publications Jouni Hirvonen
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki, Finland
3 shared publications- Marianna Kemell
Department of Chemistry, University of Helsinki, Helsinki, Finland
3 shared publications Anni Heinonen
Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki FI-00014 Helsinki, Finland
2 shared publications
Latest Publications
- Open Access
- 6 June 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 700, 127053
Dairy industry side-stream lactose as a surrogate for commercial products during major supply disruptions
- 6 June 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 700, 127053
Open AccessDairy industry side-stream lactose as a surrogate for commercial products during major supply disruptions
- Open Access
- 26 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 698, 126915
Dissolution screening of drug nanosuspensions using in situ UV–vis spectroscopy
- 26 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 698, 126915
Open AccessDissolution screening of drug nanosuspensions using in situ UV–vis spectroscopy
- Open Access
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Dissolution screening of drug nanosuspensions using in situ UV-vis spectroscopy
The study assessed the usability of in situ UV-vis spectroscopy for differentiating drug nanosuspensions based on their solubility and dissolution. In situ UV-vis spectroscopy has been applied for dissolution testing of drug nanosuspensions. However, uncertainty in applying the technique arises from the possibility that submicron particles can promote quantification error. To reassess usability, model nanosuspension formulations of itraconazole were produced with particle sizes ranging from 247 to 1168 nm. These formulations were subjected to solubility and dissolution analysis using in situ 2nd derivative UV-vis spectroscopy under non-sink conditions. Results indicated that submicron particles indeed caused errors in the concentration values obtained during dissolution experiments. Nevertheless, the data could be used to rank formulations based on their initial dissolution rate. In conclusion, in situ 2nd derivative UV-vis spectroscopy was found to be usable for dissolution screening of drug nanosuspensions even if excess submicron drug particles were present.
- 17 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessDissolution screening of drug nanosuspensions using in situ UV-vis spectroscopy
The study assessed the usability of in situ UV-vis spectroscopy for differentiating drug nanosuspensions based on their solubility and dissolution. In situ UV-vis spectroscopy has been applied for dissolution testing of drug nanosuspensions. However, uncertainty in applying the technique arises from the possibility that submicron particles can promote quantification error. To reassess usability, model nanosuspension formulations of itraconazole were produced with particle sizes ranging from 247 to 1168 nm. These formulations were subjected to solubility and dissolution analysis using in situ 2nd derivative UV-vis spectroscopy under non-sink conditions. Results indicated that submicron particles indeed caused errors in the concentration values obtained during dissolution experiments. Nevertheless, the data could be used to rank formulations based on their initial dissolution rate. In conclusion, in situ 2nd derivative UV-vis spectroscopy was found to be usable for dissolution screening of drug nanosuspensions even if excess submicron drug particles were present.
- Open Access
- 8 August 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 213, 107230
The effect of formulation composition and flow conditions on the robustness of semisolid extrusion 3D printing: a case study on poorly water-soluble itraconazole for oral dosage form production
- 8 August 2025
- Published by Elsevier in European Journal of Pharmaceutical Sciences
- Vol. 213, 107230
Open AccessThe effect of formulation composition and flow conditions on the robustness of semisolid extrusion 3D printing: a case study on poorly water-soluble itraconazole for oral dosage form production
- Open Access
- 17 June 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 660, 124354
Use of dairy industry side-stream lactose for tablet manufacturing − proof of concept study
- 17 June 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 660, 124354
Open AccessUse of dairy industry side-stream lactose for tablet manufacturing − proof of concept study
- Open Access
- 28 March 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 655, 124070
Rheological insights into 3D printing of drug products: Drug nanocrystal-poloxamer gels for semisolid extrusion
- 28 March 2024
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 655, 124070
Open AccessRheological insights into 3D printing of drug products: Drug nanocrystal-poloxamer gels for semisolid extrusion